Questcor (QCOR -34.5%) is getting hammered this morning on another negative report from Citron...

|By:, SA News Editor

Questcor (QCOR -34.5%) is getting hammered this morning on another negative report from Citron Research. Citron is saying that Aetna (AET -0.5%) has dropped almost all coverage of QCOR's drug Achtar for treating multiple sclerosis and nephrotic symdrome, saying that studies found no proof of efficacy to substantiate reimbursement. It will, however, continue to provide reimbursement when treating infantile spasms.